We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

58 hedge funds and large institutions have $33.1M invested in Regulus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 19 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 19

0.05% less ownership

Funds ownership: 0.37% → 0.32% (-0.05%)

15% less funds holding

Funds holding: 68 → 58 (-10)

37% less capital invested

Capital invested by funds: $52.9M → $33.1M (-$19.8M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

87% less call options, than puts

Call options by funds: $14K | Put options by funds: $107K

Holders
58
Holders Change
-10
Holders Change %
-14.71%
% of All Funds
1.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
20
Reduced
19
Closed
15
Calls
$14K
Puts
$107K
Net Calls
-$93K
Net Calls Change
+$156K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.37M
2
EC
EcoR1 Capital
California
+$2.39M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.34M
4
BI
BVF Inc
California
+$988K
5
ARTA
A.R.T. Advisors
New York
+$295K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$10.5M
2
Axa
Axa
France
-$2.4M
3
Millennium Management
Millennium Management
New York
-$847K
4
BCM
Bridgeway Capital Management
Texas
-$342K
5
Renaissance Technologies
Renaissance Technologies
New York
-$322K
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
51
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3K -$12.9K -68 -84%
PAM
52
Panagora Asset Management
Massachusetts
$3K +$3.04K +16 New
MAM
53
Meeder Asset Management
Ohio
$2K -$11.6K -61 -84%
CG
54
Cutler Group
California
$2K -$8.76K -46 -77%
Citigroup
55
Citigroup
New York
$1K -$60.9K -320 -98%
MA
56
MUFG Americas
New York
$1K – – –
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$563 -$2.85K -15 -83%
SIM
58
Sonora Investment Management
Arizona
$330 – – –
Wellington Management Group
59
Wellington Management Group
Massachusetts
– -$10.5M -39,029 Closed
Axa
60
Axa
France
– -$2.4M -8,884 Closed
Millennium Management
61
Millennium Management
New York
– -$847K -3,135 Closed
T. Rowe Price Associates
62
T. Rowe Price Associates
Maryland
– -$257K -953 Closed
VKH
63
Virtu KCG Holdings
New York
– -$148K -547 Closed
D.E. Shaw & Co
64
D.E. Shaw & Co
New York
– -$139K -516 Closed
RFCA
65
R&F Capital Advisors
New York
– -$70K -260 Closed
Squarepoint
66
Squarepoint
New York
– -$66K -245 Closed
PP
67
Paloma Partners
Connecticut
– -$55K -204 Closed
BCM
68
Bourgeon Capital Management
Connecticut
– -$54K -199 Closed
CS
69
Credit Suisse
Switzerland
– -$35K -132 Closed
Dimensional Fund Advisors
70
Dimensional Fund Advisors
Texas
– -$30K -112 Closed
Wolverine Trading
71
Wolverine Trading
Illinois
– -$25K -94 Closed
CLOS
72
Compagnie Lombard Odier SCmA
Switzerland
– -$11K -42 Closed
1 2
3

RGLS Hedge Fund Activity: Q1 2017 in Review

58 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2017, worth a combined $33.1M — down 37% from $52.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of RGLS and 9 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 20 added.

The largest buyer was BlackRock, adding an estimated $3.37M. The largest seller was Wellington Management Group, exiting entirely with an estimated $10.5M sold.

  • 58 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2017, down from 68 in Q4 2016.
  • Funds reported $33.1M of Regulus Therapeutics stock for Q1 2017, down 37% quarter-over-quarter.
  • 9 funds opened new Regulus Therapeutics positions in Q1 2017 and 15 closed out, a net change of -6 holders.
  • The largest Regulus Therapeutics buyer in Q1 2017 was BlackRock, an estimated $3.37M added.
  • The largest Regulus Therapeutics seller in Q1 2017 was Wellington Management Group, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2017.